<DOC>
	<DOCNO>NCT01738425</DOCNO>
	<brief_summary>The objective single center , randomize , double-blinded , placebo-controlled Phase I clinical study evaluate safety tolerability five ( 5 ) single four ( 4 ) multiple increase oral dos GIC-1001 compare placebo , evaluate pharmacokinetics GIC-1001 follow single multiple-dose administration 80 healthy , 18-50 year old male female subject . Moreover , effect food pharmacokinetics GIC-1001 healthy subject assess . This study design integrate , adaptive approach allow evaluation single multiple dose GIC-1001 progressive , overlapped fashion .</brief_summary>
	<brief_title>A Clinical Phase I Study GIC-1001 Healthy Volunteers</brief_title>
	<detailed_description>Each cohort enrol healthy volunteer include total eight ( 8 ) subject : Six ( 6 ) subject randomize active GIC-1001 two ( 2 ) subject randomize match placebo . Part 1 : Single Doses Cohort A : Single dose 125 mg GIC-1001 placebo ; Cohort B : Single dose 250 mg GIC-1001 placebo ; Cohort C : Single dose 375 mg GIC-1001 placebo ; Cohort D : Single dose 500 mg GIC-1001 placebo ; Cohort E : Single dose 1000 mg GIC-1001 placebo . Up 21 blood sample obtain 36 hour period . Part 2 : Multiple Doses , three time day ( TID ) 7 consecutive day ; Cohort F : Multiple dos 125 mg GIC-1001 placebo ; Cohort G : Multiple dos 250 mg GIC-1001 placebo ; Cohort H : Multiple dos 375 mg GIC-1001 placebo ; Cohort I : Multiple dos 500 mg GIC-1001 placebo . Up 18 blood sample obtain 7 day period . Part 3 : one single dose GIC-1001 select Food Effect cross-over evaluation . A total 16 blood sample obtain 36 hour period . Physical exam , 24 hour cardiac monitoring , complete battery biochemical hematological lab test do assess safety tolerability GIC-1001 dosing cohort .</detailed_description>
	<mesh_term>Colonic Diseases</mesh_term>
	<mesh_term>Hydrogen Sulfide</mesh_term>
	<criteria>1 . Male female volunteer 2 . A female volunteer must meet one follow criterion : 1 . Participant childbearing potential agrees use one accept contraceptive regimen screen visit 2 month last drug administration . 2 . Participant nonchildbearing potential , define female hysterectomy tubal ligation , clinically consider infertile menopausal state ( least 1 year without menses ) 3 . A male volunteer sexual partner pregnant , possibly pregnant , could become pregnant must meet following criterion : Participant agree use one accept contraceptive regimen first drug administration 3 month last drug administration . 4 . Volunteer age least 18 year old 50 year 5 . Volunteer body mass index ( BMI ) great equal 18.50 30 kg/m2 6 . Non exsmokers . An exsmoker define someone completely stop smoke least 6 month day 1 study 7 . Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance 8 . Have clinically significant disease capture medical history evidence clinically significant finding physical examination and/or clinical laboratory evaluation ( hematology , biochemistry , ECG urinalysis ) 1 . History significant hypersensitivity trimebutine , sulfur contain drug ( e.g . Captopril ) relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug 2 . Presence significant gastrointestinal , liver/kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect 3 . History significant gastrointestinal , liver kidney disease may affect drug bioavailability 4 . Presence significant cardiovascular , pulmonary , hematologic , neurological , psychiatric , endocrine , immunologic dermatologic disease 5 . Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease 6 . Presence outofrange cardiac interval ( PR &lt; 110 msec , PR &gt; 200 msec , QRS &lt; 60 msec , QRS &gt; 110 msec QTc &gt; 440 msec ) screen ECG clinically significant ECG abnormalities 7 . Known presence rare hereditary problem galactose /or lactose intolerance 8 . Use cysteine , methionine , sulfur contain amino acid supplement previous 7 day day 1 study 9 . Maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) 10 . Any clinically significant illness previous 28 day day 1 study 11 . Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin , rifampin St John 's Wort ) , previous 28 day day 1 study 12 . Any history tuberculosis and/or prophylaxis tuberculosis 13 . Positive urine screen ethanol and/or drug abuse 14 . Positive result HIV , HBsAg antiHCV test 15 . Females pregnant accord positive serum pregnancy test 16 . Volunteers take Investigational Product ( another clinical trial ) donate 50 mL blood previous 28 day day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>GIC-1001</keyword>
	<keyword>opioid agonist</keyword>
	<keyword>sulfide</keyword>
	<keyword>colonoscopy</keyword>
	<keyword>gicare</keyword>
	<keyword>Phase I</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy subject</keyword>
	<keyword>single ascend dose</keyword>
	<keyword>multiple ascend dose</keyword>
	<keyword>SAD</keyword>
	<keyword>MAD</keyword>
	<keyword>food effect</keyword>
</DOC>